Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ Factual Report
Provider: Reuters Investment Profile
Provider: Crystal Research Associates

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Therapeutics Inc Closes $5.3 Million In Private Placement Of Common Stock And Warrants

Thursday, 3 Oct 2013 10:19am EDT 

Boston Therapeutics Inc announced that it has closed the final tranche of approximately $1.8 million to bring total gross proceeds of approximately $5.3 million from the private placement of Common Stock and warrants to existing and new accredited investors (the Offering). Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes. PAZ320 is the first compound in a new class of therapies for this disease. Laidlaw Ltd., a FINRA-registered broker dealer, acted as the exclusive placement agent with respect to the Offering. 

Company Quote

-0.061 -11.96%
26 Aug 2014